RxSight, Inc. RXST Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 77%+5.1pp | 76.6%+5.9pp | 75%+6.5pp | 73.1%+6.9pp | 71.9%+8.5pp | |
| Operating margin | -43.4%-18.6pp | -35.8%-9.5pp | -32%-1.5pp | -28.9%+7.9pp | -24.9%+22.3pp | |
| Net margin | -36.6%-18.7pp | -29%-9.3pp | -25.1%-1.2pp | -21.9%+10.0pp | -17.9%+26.1pp | |
| Returns | ||||||
| Return on equity | -17.1%-5.1pp | -14%-1.6pp | -12.9%+1.1pp | -11.7%+5.3pp | -12%+16.8pp | |
| Return on invested capital | -21.1%-2.6pp | -17.7%-0.6pp | -17.2%+1.1pp | -16.6%+2.9pp | -18.6%+11.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×-0.2× | 0.4×-0.1× | 0.5×-0.1× | 0.5×0.0× | 0.6×+0.1× | |
| Liquidity | ||||||
| Current ratio | 10.2×-2.5× | 10.9×-0.4× | 12.7×+0.1× | 13.9×-0.4× | 12.7×+3.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.47-6.1% | $6.75-6.7% | $6.74-3.3% | $6.82-4.7% | $6.90+55.0% | |
| Valuation | ||||||
| Market capitalization | $232.23M-56.8% | $428.44M-69.1% | $367.83M-80.6% | $556.73M-74.9% | $1.02B-46.2% | |
| Price / sales | 1.8×-1.8× | 3.2×-6.7× | 2.6×-12.2× | 3.8×-15.5× | 6.9×-11.9× | |
| Price / book | 0.9×-1.1× | 1.6×-3.4× | 1.3×-5.5× | 2×-6.1× | 3.7×-7.9× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are RxSight, Inc.'s profit margins?
- RxSight, Inc. (RXST) runs a 77.0% gross margin and a -43.4% operating margin, with a -36.6% net margin.
- Where do RxSight, Inc.'s ratios come from?
- Every ratio is computed from RxSight, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
